养心定悸胶囊联合美托洛尔对冠心病合并快速型心律失常患者的临床疗效

Clinical Efficacy of Yangxin Dingji Capsule Combined with Metoprolol on Patients with Coronary Heart Disease Complicated with Rapid Arrhythmia

目的:研究养心定悸胶囊联合美托洛尔对冠心病合并快速型心律失常患者的临床疗效。方法:选择2017年1月至2017年12月期间在我院接受诊治的86例冠心病合并快速型心律失常患者作为观察对象,参照随机数表法原则分成对照组、研究组,各43例。对照组患者接受口服美托洛尔治疗,研究组患者接受口服养心定悸胶囊联合美托洛尔治疗。对比两组患者治疗效果及治疗前后心功能、血液流变学变化。结果:研究组患者的治疗总有效率83.7%(36/43)高于对照组的67.4%(29/43),差异有统计学意义(P <0.05);治疗后两组患者的HR水平均低于治疗前,且研究组低于对照组,差异有统计学意义(P <0.05);治疗后两组患者的LVEF水平均高于治疗前,且研究组高于对照组,差异有统计学意义(P <0.05);治疗后两组患者的纤维蛋白原、高切全血黏度、血浆黏度、低切全血粘度水平均低于治疗前,且研究组低于对照组,差异有统计学意义(P <0.05)。结论:养心定悸胶囊联合美托洛尔对冠心病合并快速型心律失常效果显著,能有效缓解临床症状,改善心功能,调节血液流变学,对心律失常进行纠正,值得临床推广。

Objective: To study the clinical efficacy of Yangxindingji capsule combined with metoprolol in patients with coronary heart disease complicated with rapid arrhythmia. Methods: A total of 86 cases of patients with coronary heartdisease complicated with tachyarrhythmia diagnosed in our hospital from January 2017 to December 2017 were selectedas the subjects of this study. All the patients were divided into a control group and a study group according to theprinciple of the random number table, with 43 cases in each group. The patients in the control group were received oralmetoprolol for treatment, and the patients in the study group were treated with oral Yangxindingji capsule combined withMetoprolol for treatment. The treatment effect and the change of heart function and blood rheology were comparedbetween the two groups before and after the treatment. Results: The total effective rate of treatment in the study group was83.7%(36/43), which was higher than that in the control group(67.4%)(29/43). The difference was statisticallysignificant(P < 0.05);After the treatment, the HR levels in both groups were lower than before treatment, and the studygroup was lower than the control group, with a significant difference(P < 0.05);The LVEF levels after treatment in thetwo groups were higher than before treatment, and the study group was higher than the control group. The difference wasstatistically significant(P < 0.05);The fibrinogen, high-cutting whole blood viscosity, plasma viscosity, and low-cutwhole blood viscosity of the two groups after treatment were lower than before treatment, and the study group was lowerthan the control group. The difference was statistically significant(P < 0.05). Conclusion: Yangxindingji capsulecombined with metoprolol has significant effects on coronary heart disease combined with rapid arrhythmia, which caneffectively relieve clinical symptoms, improve cardiac function, regulate hemorheology, correct arrhythmia, and is worthy of clinical promotion.